Medical Affairs Consulting
Medical affairs consulting helps pharmaceutical and biotech companies turn scientific evidence into clinical impact. Speyside Health begins by understanding the landscape and its stakeholders in depth, then builds the strategy, and the surrounding ecosystem, that carries a programme or a new treatment from scientific rationale to adoption in practice, supporting implementation and the breadth of activity that real uptake requires.
Our medical affairs services
We work across the therapeutic landscape, with documented depth in the areas below. Each groups the specific conditions our teams have delivered on:
Medical and scientific strategy
connecting global medical objectives to local execution across the product lifecycle, market by market, including regional and local medical strategy adaptation.
Scientific narrative and messaging
translating clinical evidence into locally relevant medical stories, and identifying unmet need, care-pathway friction and evidence gaps.
Expert and stakeholder engagement
KOL, HCP and patient-advocacy strategy; advisory boards, steering committees, consensus meetings and expert roundtables (KOLs, policy, patients and multidisciplinary teams).
Scientific exchange and publications
publication planning, scientific exchange, congress support, and medical education materials and educational programmes.
Evidence planning and dissemination
RWE and HEOR planning and evidence dissemination to meet the requirements of regulators, payers and clinicians.
Scientific and medical communications
accurate, compliant medical content across audiences and channels.
How do we build KOL and stakeholder engagement in complex markets?
We start from a structured stakeholder architecture, who to engage, through which tactics, at which lifecycle stage, validated by in-country consultants rather than desk research alone. Mapping goes beyond the obvious names: we dig deeper to surface the hidden connections and informal influence between stakeholders, so that every potential advocacy pathway is considered, not only the visible ones. And we work to understand the evidence each party actually needs, clinical, regulatory, payer and patient, so engagement is built on what will move each decision. Plans are measured on uptake and impact, changes in clinical practice, guidelines and access, not activity counts.
FAQ
FAQ answers to be drafted at ~60–100 words each, answer-first; mark up with FAQPage schema at build.
FAQ answers to be drafted at ~60–100 words each, answer-first; mark up with FAQPage schema at build.
FAQ answers to be drafted at ~60–100 words each, answer-first; mark up with FAQPage schema at build.